Airway mucus plays a critical role in clearing inhaled toxins, particles, and pathogens. Diverse toxic, inflammatory, and infectious insults induce airway mucus secretion and goblet cell metaplasia to preserve airway sterility and homeostasis. However, goblet cell metaplasia, mucus hypersecretion, and airway obstruction are integral features of inflammatory lung diseases, including asthma, chronic obstructive lung disease, and cystic fibrosis, which cause an immense burden of morbidity and mortality. These chronic lung diseases are united by susceptibility to microbial colonization and recurrent airway infections. Whether these twinned phenomena (mucous metaplasia, compromised host defenses) are causally related has been unclear. Here, we demonstrate that SAM pointed domain ETS factor (SPDEF) was induced by rhinoviral infection of primary human airway cells and that cytoplasmic activities of SPDEF, a transcriptional regulator of airway goblet cell metaplasia, inhibited Toll-like receptor (TLR) activation of epithelial cells. SPDEF bound to and inhibited activities of TLR signaling adapters, MyD88 and TRIF, inhibiting MyD88-induced cytokine production and TRIF-induced interferon β production. Conditional expression of SPDEF in airway epithelial cells in vivo inhibited LPSinduced neutrophilic infiltration and bacterial clearance. SPDEFmediated inhibition of both TLR and type I interferon signaling likely protects the lung against inflammatory damage when inciting stimuli are not eradicated. Present findings provide, at least in part, a molecular explanation for increased susceptibility to infection in lung diseases associated with mucous metaplasia and a mechanism by which patients with florid mucous metaplasia may tolerate microbial burdens that are usually associated with fulminant inflammatory disease in normal hosts.
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airway epithelium | innate immunity F or efficient gas exchange to occur, the lung maintains an enormous (∼100 m 2 in humans), thin (two cells thick, from bloodstream to airstream) membrane in direct contact with the outside environment. This interface is susceptible to compromise by the destructive power of microbes introduced with ∼10 L/min of inspired air. The lung is just as susceptible to compromise by the destructive power of inflammatory responses generated in response to microbial insult. It is thus unsurprising that the airways and alveoli of the lung are equipped with a wide array of innate immune defenses that facilitate microbial clearance and killing without inducing inflammation, including mucociliary clearance, abundant noninflammatory macrophages, and the constitutive (and inducible) presence of diverse opsonic and antimicrobial proteins in airway fluids (1-3). In turn, immune activation is tightly regulated in the lung by a variety of mechanisms (4) (5) (6) (7) . When pulmonary inflammatory responses are necessary, their class, amplitude, and time course are kept under tight control in the lung. In all of this, airway epithelial cells play a central role, effecting mucociliary clearance, acting as critical sentinels and effectors of the pulmonary innate immune system, and interacting in complex ways with hematopoietic cells to regulate immune activation, class specification, and resolution after infection (8) . Dysregulation of any of these parameters can impair gas exchange, either acutely or through the destructive, chronic remodeling processes that often occur when pulmonary infection and inflammation fail to resolve.
The barrier, clearance, and hydration functions of airway mucus, produced by secretory epithelial cells lining the airways (as well as by submucosal glands in large airways), play critical roles in protecting the lung from microbial, toxic, and inflammatory injury (1) . Exposure to such insults leads to induction of airway mucus production along with recruitment of mucus secretion capacity, the latter through submucosal gland hyperplasia as well as through mucous metaplasia, which is the rapid, reversible differentiation of basal cells and other secretory cell progenitors into airway goblet cells. A transcriptional program driving airway mucous metaplasia in the airway epithelium has recently been defined. SAM pointed domain ETS factor (SPDEF) is critical to this process, functioning in a cell-autonomous manner in the respiratory epithelium. Increased SPDEF expression is closely associated with mucus cell metaplasia and mucus hyperproduction in lungs of asthmatics, patients with cystic fibrosis, and those with chronic obstructive lung disease and in mouse models of allergic pulmonary inflammation, wherein SPDEF is induced by TH 2 -cytokine signaling via Stat6 (9) . SPDEF is both necessary and sufficient to regulate a transcriptional network that drives the expression of genes regulating goblet cell differentiation, including those mediating mucin production, glycosylation, packaging, and secretion and those inhibiting the expression of genes characteristically expressed by normal airway epithelial cells (9, 10) .
Although likely beneficial in microbial clearance in the short term, when chronic, airway mucous metaplasia and hypersecretion are thought to contribute to the pathogenesis of diverse inflammatory diseases, including chronic obstructive pulmonary disease, bronchiectasis, asthma, and cystic fibrosis. Paradoxically, despite ongoing inflammation, patients with both acute and chronic disease associated with mucous metaplasia exhibit heightened susceptibility to microbial colonization and infection of the airway. Likewise, secondary or mixed viral and bacterial infections are common complications in chronic lung diseases (11) (12) (13) . The present study demonstrates that the Ets family transcription factor SPDEF, a transcriptional regulator required for airway mucous metaplasia, plays an unexpected role in suppressing innate immune signaling, suggesting a molecular mechanism that could inhibit inflammation while contributing to susceptibility to infection associated with chronic airway disease.
Results

SPDEF-Driven Mucous Metaplasia Blunts Lipopolysaccharide-Driven
Inflammation in the Airway. The susceptibility to pulmonary infection associated with chronic airway diseases, together with the centrality of airway epithelial cells to host defense of the lung, suggested that mucous metaplasia might directly modulate the immune responsiveness of airway epithelial cells. To address this, we used transgenic mice with conditional expression of SPDEF under control of the Clara cell secretory protein promoter driven reverse tetracycline transactivator (Scgb1a1[CCSP]-rtTA/Tre2-Spdef mice). Treatment of these mice with doxycycline selectively drives robust goblet cell metaplasia in the conducting airways (9) without the confounding effects associated with airway inflammation caused by noxious external stimuli that are required to induce mucus production in the murine airway. In the normal mouse, Toll-like receptor (TLR) challenge of the airway leads to a brisk, neutrophilic inflammatory response (Fig. 1) . In mice expressing SPDEF in the respiratory epithelium, mucous metaplasia was associated with significant inhibition of production of the neutrophil chemokine, KC, and neutrophil infiltration into the airways in response to both acute and subacute repeated challenge of the airway with LPS ( Fig (10) is impractical, because wild-type controls kept under specific pathogen-free conditions do not have airway mucous metaplasia and lack SPDEF expression. Furthermore, known strategies to induce goblet cell metaplasia, e.g., expression of Th 2 -cytokines or pulmonary allergic sensitization, require chronic inflammatory stimuli, and the associated inflammation influences innate defenses. SPDEF inhibited LPSinduced inflammation, demonstrating that SPDEF-induced mucous metaplasia plays a counter-regulatory role in restraining innate immune responses to TLR challenge of the airway.
SPDEF Inhibits TLR Signaling in Airway Epithelial Cells. SPDEF expression and mucous metaplasia are induced both by interleukin (IL)-13 in Th 2 -mediated inflammatory processes, after loss of FOXA2, and in clinical settings associated with chronic lung inflammation (9, 10, 14) . We found that mucous metaplasia, SPDEF, and genes associated with mucus hyperproduction were markedly induced by IL-13 in primary human airway epithelial cells in vitro ( Fig. 2 A-E). Likewise, infection by rhinovirus induced SPDEF and MUC5AC mRNAs (Fig. 2F ). This association between SPDEF and mucous metaplasia is consistent with previous studies in murine models of experimental asthma and immunohistochemistry in lung tissue from patients with asthma, cystic fibrosis, and smoking habits (9, 10) . The effects of SPDEF and associated mucous metaplasia on airway epithelial innate immune function could occur either indirectly, such as through rheologic alteration to influence the access of exogenous stimuli to responding cells related to changes on the mucus barrier or directly, such as through alteration of the responsiveness of airway epithelial cells to LPS (e.g., by regulating Muc1 expression, a known regulator of TLR signaling) (15) . However, SPDEF did not induce Muc1 mRNA in airway epithelial cells in the mouse (10) . To test whether SPDEF directly influenced TLR signaling, we examined the effect of SPDEF on TLR signaling in HEK293T cells, which are tractable cells with fully functional TLR signaling machinery that have been extensively used to identify components of the complex TLR signaling pathways (16) . Expression of SPDEF in HEK293T cells caused dose-dependent inhibition of a nuclear factor (NF)-κB reporter construct, pELAM luc, in response to TLR2, TLR3, TLR4, and TLR5 stimulation (Fig. 3 A-D) . Because SPDEF inhibited signaling via multiple TLRs, we tested whether it influenced the activity of the TLR/IL-1/resistance (TIR)-containing adaptor proteins, MyD88 and TRIF (17) . Of note, SPDEF expression significantly suppressed NF-κB transactivation in response to MyD88 in both HEK293T (Fig. 3E ) and primary human bronchial epithelial cells (Fig. 3F ) and significantly suppressed both NF-κB-and IFN response factor-dependent promoter transactivation in response to TRIF expression in HEK293T cells ( Fig. 3 G and H) . Consistent with these inhibitory effects, SPDEF significantly inhibited IL-8 mRNA in response to LPS stimulation or MyD88 expression in HEK293T cells and inhibited IL-6, IL-8, and IL-1β proinflammatory cytokine mRNA expression in A549 cells, a human airway epithelial cell line (Fig.  4) . SPDEF also inhibited IFN-β mRNA expression in response to expression of TRIF in HEK293T cells (Fig. 4F) . Thus, SPDEF caused cell-autonomous inhibition of TLR signaling in HEK293T cells, in primary, nontransformed bronchial epithelial cells, and in A549 adenocarcinoma cells, supporting its counter-regulatory role in innate immune activation in respiratory epithelial cells.
SPDEF Interacts Directly with MyD88 and TRIF. The ability of SPDEF to restrain signaling driven by expression of MyD88 and TRIF suggested that the locus of SPDEF-mediated inhibition of TLR signaling was at the level of, or downstream of, these critical adaptor proteins. In addition to the four signaling TIR-containing adaptors (MyD88, TRIF, TRAM, and Mal), a fifth TIRcontaining adaptor protein, SARM, negatively regulates TLR signaling via effects on both TRIF and MyD88 (18, 19) . In the case of TRIF, direct interactions with SARM have been demonstrated by coimmunoprecipitation techniques (18) . Intriguingly, the SAM domain of SPDEF exhibits considerable sequence homology with the SAM domain of SARM, suggesting the possibility of direct interactions between SPDEF and these adaptor proteins. Direct association of SPDEF with MyD88 was demonstrated by bidirectional coimmunoprecipitation in lysates of HEK293T cells coexpressing epitope-tagged SPDEF along with MyD88 (Fig. 5A) . Direct association of SPDEF with TRIF was shown by similar means (Fig. 5C ). Confocal microscopy revealed cytoplasmic colocalization of SPDEF with MyD88 ( Fig.  5B) and TRIF (Fig. 5D ) in HEK293T cells. Coimmunoprecipitation and confocal microscopy revealed that coexpression with MyD88 and TRIF led to increased SPDEF concentrations in these cells. Thus, SPDEF can interact directly with MyD88 and TRIF in the nonnuclear compartment, a finding that supports the concept that SPDEF may restrain inflammation via interactions with these adaptor proteins, thereby limiting TLR signaling. We also tested whether MyD88 might influence transcriptional activity of SPDEF on the Agr2 promoter in transfection experiments in BEAS2B cells. Although SPDEF and SPDEF in the presence of FOXA3 induced the Agr2 promoter in vitro, MyD88 did not alter these responses (Fig. S2) . As might be expected, initial mutational analysis of SPDEF indicated a clear role for the SAM domain of SPDEF in suppression of MyD88-dependent signaling (Fig. S3) . In structural studies, six MyD88 molecules oligomerize and form a helical tower with IRAK4 and IRAK2 (20) . SAM domains are also known to oligomerize and form helical assemblies (21, 22) . One possibility suggested by these analogies and our experimental observations is that a helical arrangement of the SPDEF SAM domains may assemble on a MyD88 helix to form a helical tower analogous to the MyD88-IRAK4-IRAK2 complex.
Mucous Metaplasia Compromises Pulmonary Antibacterial Responses.
Although the mechanistic focus in these studies was on regulation of TLR signaling, the finding that rhinovirus induced SPDEF . Experiments were performed in at least triplicate using independent donor samples (n ≥ 3), mean fold change ± SEM. HAEC ALI cultures from normal donor samples were exposed to rhinovirus RV16 and mRNA assessed by qRT-PCR 48 h after infection. White bars represent uninfected cells, black bars cells infected with rhinovirus at a multiplicity of infection of 5. Data are mean ± SEM from two independent donor samples, with 2-3 technical replicates per condition. *P = 0.001, **P = 0.04, ***P = 0.05. Student's t test. Fig. 3 . SAM pointed domain ETS factor (SPDEF) inhibits Toll-like receptor (TLR) signaling. HEK293T cells (A, E, G, and H) were cotransfected with reporters (pELAM-luc or pISRE-luc and pRL-TK) and plasmids described for each condition. Effects of SPDEF expression plasmids were assessed by luciferase assay. Thirty hours after transfection, cells were stimulated with TLR ligand or with phosphate-buffered saline for 18 h. (A) Cells were cotransfected with plasmids expressing TLR4, CD-14, and MD-2 with or without SPDEF and treated with 10 ng/mL Escherichia coli lipopolysaccharide, four experiments, n = 10-12 per condition. (B) HEK293/TLR2/CD-14 cells were transfected with or without SPDEF and exposed to 100 ng/mL Pam3Cys, two experiments, n = 6 per condition. (C ) HEK293/TLR5 cells were transfected with or without SPDEF and treated with 100 ng/mL flagellin, four experiments, n = 12 per condition. (D) HEK293/TLR3 cells were transfected with or without pCMV-Flag-SPDEF and treated with 10 μg/mL Poly (I:C), two experiments, n = 4 per condition. HEK293T cells were cotransfected with pEF-BOS-MyD88 (E) with or without SPDEF, six experiments, n = 18 per condition. (F) Primary human airway epithelial cells were cotransfected with pEF-BOS-MyD88 with or without SPDEF, two experiments, n = 6 per condition. (G) Cells were cotransfected with pEF-BOS-TRIF with or without SPDEF, two experiments, n = 6 per condition. (H) Cells were cotransfected with pISRE-Luc and pEF-BOS-TRIF with or without SPDEF, three experiments, n = 9 per condition. Data are mean ± SEM. *P ≤ 0.05, **P ≤ 0.001. Student's t test. expression suggested a possible role for SPDEF in modulating IFN-β signaling as well. Indeed, SPDEF inhibited IFN-β-induced expression of pISRE-luciferase in HEK293T cells, indicating that SPDEF may play a wider role in restraining innate immune activation that includes inhibition of IFN-β responses (Fig. S4) . Such broad counter-regulation of innate immune responses by SPDEF suggests a possible mechanism underlying the ability of patients with diseases marked by florid, chronic mucous metaplasia, such as chronic obstructive pulmonary disease, bronchiectasis, and cystic fibrosis, to tolerate lung microbial burdens that would be associated with fulminant inflammatory disease in normal hosts or be susceptible to secondary infection following acute viral illness that caused mucus metaplasia. We therefore directly tested whether SPDEF might provide a molecular explanation for the increased susceptibility to colonization and infection that are associated with mucous metaplasia. As previously described, treatment of Scgb1a1-rtTA/ Tre2-Spdef transgenic mice induced diffuse mucous metaplasia in conducting airways (9, 10) . Control-and SPDEF-expressing transgenic mice were treated intratracheally with Klebsiella pneumoniae. Expression of SPDEF was associated with significant blunting of pulmonary antimicrobial responses required for bacterial clearance (Fig. S5) .
Discussion
The finding that SPDEF plays an epithelial cell autonomous role in the regulation of innate immune responses in the respiratory epithelium provides an unanticipated causal link between mucous metaplasia, suppression of innate immune signaling, inflammation, and susceptibility to pulmonary infection. Patients with chronic pulmonary goblet cell metaplasia are highly susceptible to viral and bacterial infections and develop disease exacerbations that lead to further deterioration in lung function. Likewise, secondary bacterial infections commonly complicate recovery from antecedent viral infections, infections themselves associated with mucus hyperproduction. The present study shows that SPDEF restrains intracellular signaling from pathogen-associated molecular patterns from Gram-positive and -negative bacteria and viruses that signal through TLRs. SPDEF inhibited TLR signaling pathways and IFN signaling pathways that originate from TLRs by binding and inhibiting the activity of critical adaptor proteins that regulate NF-κB and IFN transcriptional responses. The present finding that SPDEF plays an epithelial cell autonomous role in the regulation of innate immunity in the lung provides a potential direct link between the process of mucous metaplasia and susceptibility to pulmonary infection and inflammation. SPDEF regulates expression of genes critical for the production of mucus, including Muc5AC, Muc16, Claca1, and Agr2, which influence mucocillary clearance of infectious pathogens from the airways. The present findings demonstrate that SPDEF also plays an anti-inflammatory role in respiratory epithelial cells by binding to and inhibiting adaptor proteins MyD88 and TRIF. These anti-inflammatory effects of SPDEF may play an important role in suppressing the potential deleterious effects of uncontrolled inflammation during the resolution of airway infections or injuries, a phase typically associated with persistent mucus production following acute respiratory infections. On the other hand, in acute and chronic pulmonary disorders associated with mucous metaplasia, SPDEF-mediated suppression of inflammation may inhibit epithelial innate immune responses needed for clearance of microbial pathogens. Thus, these dual functions of SPDEF in the airway epithelium provide a potential molecular explanation for both susceptibility to infection and failure to completely clear pulmonary pathogens that is commonly associated with chronic airway diseases. Although the present study supports a cell autonomous role for SPDEF in the respiratory epithelium, it is also possible that chronic expression of SPDEF alters inflammatory processes indirectly by affecting other lung cell types. Because SPDEF induces the expression of mucins and mucus-related genes, changes in bacterial clearance are likely influenced by rheologic consequences of mucous metaplasia and associated airway obstruction that may contribute to the persistent infections associated with cystic fibrosis and other chronic lung disorders. Whether SPDEF and associated mucous metaplasia influence processes in ciliated or basal cells to alter inflammation and mucociliary clearance is presently unknown.
The counter-regulatory mechanism supported by the present findings provides support for a tissue-specific transcriptional pathway to limit inflammatory processes. This is in contrast to the general pathways by which immune activation is resolved that also render the host susceptible to secondary infections. For example, endotoxin tolerance, the inhibition of subsets of TLRdriven responses associated with ongoing infection or bacterial product exposure, provides protection from the pathologic hyperactivation of innate immunity at the cost of risk of superinfection (23) . Likewise, in the adaptive immune system, T-cell exhaustion protects against immunopathology at the risk of sustained viral replication and viral persistence (24) . Additionally, SPDEF is induced in a Th 2 environment representing a shift from the TH1/17 antibacterial environment. SPDEF expression may contribute to the bacterial susceptibility described in an allergic environment in the lung (25, 26) .
SPDEF is a member of a large family of transcription factors that share the ETS DNA binding domain. SPDEF is distinguished from many ETS transcription factors in containing distinct SAM pointed domain and noncanonical transcriptional binding motifs that place it as a distant member of this family of transcription factors (27, 28) . SPDEF is also expressed in epithelial cells in the prostate, mammary gland, and gastrointestinal tract (29) (30) (31) , all sites that must maintain careful immune surveillance to maintain sterility or normal homeostasis in the face of pathogens or normal bacterial colonization, respectively.
Neither mucous metaplasia nor expression of SPDEF is typical of the normal respiratory tract, but both are rapidly induced by Th 2 -inflammatory process, infection, and chronic injury. Thus, expression of SPDEF is closely linked to mucous metaplasia in chronic airway diseases, including asthma, cystic fibrosis, and chronic obstructive pulmonary disease, and is likely to be involved in the pathogenesis of mucus hyperproduction following acute respiratory viral infections. The present findings demonstrate that SPDEF is rapidly induced following rhinovirus infection of human airway epithelial cells. The expression of SPDEF causes mucous metaplasia and enhances the expression of groups of genes associated with the synthesis, glycosylation, and packaging of mucus and also influences the expression of a diverse array of airway peptides that play roles in innate immunity (10) . Thus, although many effects of SPDEF are likely mediated by its role in gene transcription in the nuclear compartment, the present study identifies a distinct, nonnuclear role for SPDEF. Consistent with the proposed role of SPDEF in the cytoplasm, we colocalized SPDEF with both TRIF and MyD88 in cytoplasmic vesicles in epithelial cells. The presence of SPDEF in the cytoplasm is consistent with the immunohistochemistry of airway epithelial cells in mouse models associated with mucous metaplasia and in patients with chronic lung disease, in which both nuclear and nonnuclear staining of SPDEF was observed (9, 10). The nuclear and nonnuclear localization of SPDEF varies among diverse organs and cell types, presumably reflecting tissue-specific regulatory functions. The proposed immune counter-regulatory role of SPDEF in the airway underscores that tight linkage between the developmental transcriptional pathways and those involved in responses to environmental stressors. In this regard, the role of SPDEF in the differentiation of intestinal goblet cells (30, 31) supports the concept that SPDEF may play an important role in restraining immune activation in response to the normal intestinal microbiota.
Materials and Methods
Mouse Models. Scgb1a1-rtTA and Scgb1a1-rtTA/TRE2-Spdef, described previously (9, 10), were treated with doxycycline as described (10) . Escherichia coli 055:B5 LPS (20 μg in 100 μL; purified by ion-exchange chromatography; Sigma) was administered intratracheally for 16 h as previously described (32) . For chronic challenge, LPS (30 μg in 30 μL) was administered intranasally on days 0, 2, 4, 7, and 9. Infection of the lung with Klebsiella pneumoniae (KPA1 serotype, cps K2) was via intratracheal delivery (33, 34) . Lung bacterial burden was quantified by plating serial dilutions of lung homogenates (34, 35) onto blood agar plates. BALF cell counts and differential were performed as described (35) . KC was quantified by enzyme-linked immunosorbent assay (R&D Systems).
In Vitro Studies. Luciferase assays in cell lines were performed essentially, as previously described using Effectene (Qiagen) instead of Fugene (35) . All transfections included pELAM-luc or pISRE-luc reporter plasmids. Firefly luciferase from pELAM-luc or pISRE-luc was quantified relative to renilla luciferase from pRL-TK as previously described (32, 35) . In experiments in Fig. 3 A-D, and Fig. S3C, 30 h after transfection, cells were stimulated with bacterial pathogenassociated molecular patterns [LPS, Pam3Cys, Flagellin, and Poly (I:C)] or phosphate-buffered saline as control. Luciferase activity was determined after 18 h by comparison with cells transfected identically but not stimulated with bacterial pathogen-associated molecular patterns. Data are reported as relative luciferase activity by comparing cells without SPDEF to cells with SPDEF. In  Fig. 3 E, G , and H and Fig. S3B , cells were transfected with pEF-BOS-MyD88 or pEF-BOS-TRIF or pEF-BOS (without MyD88 or TRIF) for 24 h and luciferase activity determined by comparing cells transfected with MyD88 or TRIF with cells with the empty vector pEF-BOS. Data are reported as relative luciferase activity determined by comparing cells without SPDEF with cells with SPDEF. Primary human airway epithelial cells were electroporated using the NEON Transfection System (Invitrogen). Firefly luciferase from pELAM-luc was quantified relative to renilla luciferase from pRL-TK as previously described (32, 35) . Significance was determined using Microsoft Excel software.
IL-13 Treatment and Rhinovirus Infection of Human Airway Epithelial Cells.
Well-differentiated primary human airway epithelial cells were cultured at air-liquid interface performed as previously described (36) and treated with IL-13 (10 ng/mL) or phosphate-buffered saline in culture medium for 5 d. Alcian blue and immunofluorescence for MUC5AC was performed (9) . For rhinovirus experiments, ALI cultures were exposed apically to ∼5 MOI of rhinovirus RV16 for 2 h and total RNA was isolated 48 h after infection. Rhinovirus RV16 was kindly provided by Dr. Albert Senft, Lovelace Respiratory Research Institute, Albuquerque, NM.
Descriptions of reagents and methods are provided in SI Materials and Methods.
